LINC01207 promotes prostate cancer progression by sponging miR‑1182 to upregulate AKT3

Qin,Daming; Ni,Cheng; Tan,Biyong; Huang,Shengfei; Deng,Bingqing; Huang,Zhihua

doi:10.3892/ol.2021.13175

LINC01207 promotes prostate cancer progression by sponging miR‑1182 to upregulate AKT3

Authors:
- Daming Qin
- Cheng Ni
- Biyong Tan
- Shengfei Huang
- Bingqing Deng
- Zhihua Huang
View Affiliations

Affiliations: Department of Radiology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan University, Enshi, Hubei 445000, P.R. China, Department of Ultrasonography, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan University, Enshi, Hubei 445000, P.R. China
Published online on: December 21, 2021 https://doi.org/10.3892/ol.2021.13175
Article Number: 57
Copyright: © Qin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer (PC) is recognized as a common malignancy in male patients. Long non‑coding RNA (lncRNA) has been implicated in the development of PC. Recently, long intergenic non‑protein coding RNA 1207 (LINC01207) has been reported to regulate the carcinogenesis of multiple cancer types. However, its role in the progression of PC remains to be determined. The aim of the present study was to investigate the expression profile, clinicopathological implication and molecular mechanism of action of LINC01207 in the progression of PC. LINC01207 expression levels were compared between PC tumor and paired normal tissue samples from The Cancer Genome Atlas. The expression of LINC01207 was further analyzed in PC cell lines and a normal prostatic cell line. The role of LINC01207 in proliferation, migration and invasion of PC cells was examined using small interfering RNA‑mediated silencing. Western blot analysis was used to investigate the changes in protein levels underlying the mechanism of action of LINC01207. The role of LINC01207 in tumorigenesis was evaluated in a xenograft model. LINC01207 was upregulated in PC tumor samples from TCGA data compared with paired normal tissue. LINC01207 expression was significantly increased in PC cells and tumor tissues compared with in normal prostate cells (RWPE1) and normal prostate tissues, respectively. Furthermore, LINC01207 silencing inhibited PC cell proliferation and colony formation and induced apoptosis. Mechanistic experiments showed that LINC01207 promoted carcinogenesis by sponging miR‑1182 to regulate the protein levels of AKT3 in PC cell lines. Thus, the findings of the present study indicated that LINC01207 might play a role in the tumorigenesis of PC and may serve as a therapeutic target for PC treatment.

View Figures

View References

1	Edwards DR, Moroz K, Zhang H, Mulholland D, Abdel-Mageed AB and Mondal D: PRL-3 increases the aggressive phenotype of prostate cancer cells in vitro and its expression correlates with high-grade prostate tumors in patients. Int J Oncol. 52:402–412. 2018.PubMed/NCBI
2	Shukla ME, Yu C, Reddy CA, Stephans KL, Klein EA, Abdel-Wahab M, Ciezki J and Tendulkar RD: Evaluation of the current prostate cancer staging system based on cancer-specific mortality in the surveillance, epidemiology, and end results database. Clin Genitourin Cancer. 13:17–21. 2015. View Article : Google Scholar : PubMed/NCBI
3	Miyake H and Fujisawa M: Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches. Int J Urol. 20:301–311. 2013. View Article : Google Scholar : PubMed/NCBI
4	Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, et al: EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 59:61–71. 2011. View Article : Google Scholar : PubMed/NCBI
5	Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C and Soloway MS: Active surveillance for prostate cancer: A systematic review of the literature. Eur Urol. 62:976–983. 2012. View Article : Google Scholar : PubMed/NCBI
6	Egidi MG, Cochetti G, Guelfi G, Zampini D, Diverio S, Poli G and Mearini E: Stability assessment of candidate reference genes in urine sediment of prostate cancer patients for miRNA applications. Dis Markers. 2015:9735972015. View Article : Google Scholar : PubMed/NCBI
7	Cochetti G, Poli G, Guelfi G, Boni A, Egidi MG and Mearini E: Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: Evaluation of potential diagnostic and prognostic role. Onco Targets Ther. 9:7545–7553. 2016. View Article : Google Scholar : PubMed/NCBI
8	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
9	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
10	Gao Q and Zheng J: microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73. Biomed Pharmacother. 97:528–534. 2018. View Article : Google Scholar : PubMed/NCBI
11	Kanwal R, Plaga AR, Liu X, Shukla GC and Gupta S: MicroRNAs in prostate cancer: Functional role as biomarkers. Cancer Lett. 407:9–20. 2017. View Article : Google Scholar : PubMed/NCBI
12	Cochetti G, Rossi de Vermandois JA, Maulà V, Giulietti M, Cecati M, Del Zingaro M, Cagnani R, Suvieri C, Paladini A and Mearini E: Role of miRNAs in prostate cancer: Do we really know everything? Urol Oncol. 38:623–635. 2020. View Article : Google Scholar : PubMed/NCBI
13	Guelfi G, Cochetti G, Stefanetti V, Zampini D, Diverio S, Boni A and Mearini E: Next generation Sequencing of urine exfoliated cells: An approach of prostate cancer microRNAs research. Sci Rep. 8:71112018. View Article : Google Scholar : PubMed/NCBI
14	Situ J, Zhang H, Jin Z, Li K, Mao Y and Huang W: MicroRNA-939 directly targets HDGF to inhibit the aggressiveness of prostate cancer via deactivation of the WNT/β-catenin pathway. Onco Targets Ther. 13:4257–4270. 2020. View Article : Google Scholar : PubMed/NCBI
15	Yu C, Wang Y, Liu T, Sha K, Song Z, Zhao M and Wang X: The microRNA miR-3174 suppresses the expression of ADAM15 and inhibits the proliferation of patient-derived bladder cancer cells. Onco Targets Ther. 13:4157–4168. 2020. View Article : Google Scholar : PubMed/NCBI
16	Zhou J, Dai W and Song J: miR-1182 inhibits growth and mediates the chemosensitivity of bladder cancer by targeting hTERT. Biochem Biophys Res Commun. 470:445–452. 2016. View Article : Google Scholar : PubMed/NCBI
17	Hou XS, Han CQ and Zhang W: MiR-1182 inhibited metastasis and proliferation of ovarian cancer by targeting hTERT. Eur Rev Med Pharmacol Sci. 22:1622–1628. 2018.PubMed/NCBI
18	Zhang D, Xiao YF, Zhang JW, Xie R, Hu CJ, Tang B, Wang SM, Wu YY, Hao NB and Yang SM: miR-1182 attenuates gastric cancer proliferation and metastasis by targeting the open reading frame of hTERT. Cancer Lett. 360:151–159. 2015. View Article : Google Scholar : PubMed/NCBI
19	Huang C, Deng H, Wang Y, Jiang H, Xu R, Zhu X, Huang Z and Zhao X: Circular RNA circABCC4 as the ceRNA of miR-1182 facilitates prostate cancer progression by promoting FOXP4 expression. J Cell Mol Med. 23:6112–6119. 2019. View Article : Google Scholar : PubMed/NCBI
20	Dillon RL, White DE and Muller WJ: The phosphatidyl inositol 3-kinase signaling network: Implications for human breast cancer. Oncogene. 26:1338–1345. 2007. View Article : Google Scholar : PubMed/NCBI
21	Liby TA, Spyropoulos P, Buff Lindner H, Eldridge J, Beeson C, Hsu T and Muise-Helmericks RC: Akt3 controls vascular endothelial growth factor secretion and angiogenesis in ovarian cancer cells. Int J Cancer. 130:532–543. 2012. View Article : Google Scholar : PubMed/NCBI
22	Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ and Roth RA: Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem. 274:21528–21532. 1999. View Article : Google Scholar : PubMed/NCBI
23	Lin HP, Lin CY, Huo C, Jan YJ, Tseng JC, Jiang SS, Kuo YY, Chen SC, Wang CT, Chan TM, et al: AKT3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf, and TSC1/TSC2. Oncotarget. 6:27097–27112. 2015. View Article : Google Scholar : PubMed/NCBI
24	Zhang F and Wu Z: Significantly altered expression of miR-511-3p and its target AKT3 has negative prognostic value in human prostate cancer. Biochimie. 140:66–72. 2017. View Article : Google Scholar : PubMed/NCBI
25	Lin HP, Jiang SS and Chuu CP: Caffeic acid phenethyl ester causes p21 induction, Akt signaling reduction, and growth inhibition in PC-3 human prostate cancer cells. PLoS One. 7:e312862012. View Article : Google Scholar : PubMed/NCBI
26	Wang G, Chen H and Liu J: The long noncoding RNA LINC01207 promotes proliferation of lung adenocarcinoma. Am J Cancer Res. 5:3162–3173. 2015.PubMed/NCBI
27	Wang M, Lu X, Dong X, Hao F, Liu Z, Ni G and Chen D: pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression. World J Surg Oncol. 13:662015. View Article : Google Scholar : PubMed/NCBI
28	Wang Y, Li Z, Zheng S, Zhou Y, Zhao L, Ye H, Zhao X, Gao W, Fu Z, Zhou Q, et al: Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers. Oncotarget. 6:35684–35698. 2015. View Article : Google Scholar : PubMed/NCBI
29	Liu C, Wang JO, Zhou WY, Chang XY, Zhang MM, Zhang Y and Yang XH: Long non-coding RNA LINC01207 silencing suppresses AGR2 expression to facilitate autophagy and apoptosis of pancreatic cancer cells by sponging miR-143-5p. Mol Cell Endocrinol. 493:1104242019. View Article : Google Scholar : PubMed/NCBI
30	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2002. View Article : Google Scholar : PubMed/NCBI
31	National Research Council (US) Committee for the Update of the Guide for the Care, Use of Laboratory Animals: Guide for the Care and Use of Laboratory Animals. (8th edition). https://grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals.pdfOctober 21–2021
32	Deng T, Yuan Y, Zhang C, Zhang C, Yao W, Wang C, Liu R and Ba Y: Identification of circulating miR-25 as a potential biomarker for pancreatic cancer diagnosis. Cell Physiol Biochem. 39:1716–1722. 2016. View Article : Google Scholar : PubMed/NCBI
33	Cai B, Song XQ, Cai JP and Zhang S: HOTAIR: A cancer-related long non-coding RNA. Neoplasma. 61:379–391. 2014. View Article : Google Scholar : PubMed/NCBI
34	Pang EJ, Yang R, Fu XB and Liu YF: Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer. Tumor Biol. 36:2403–2407. 2015. View Article : Google Scholar : PubMed/NCBI
35	Wang S, Qiu J, Wang L, Wu Z, Zhang X, Li Q and Jiang F: Long non-coding RNA LINC01207 promotes prostate cancer progression by downregulating microRNA-1972 and upregulating LIM and SH3 protein 1. IUBMB Life. 72:1960–1975. 2020. View Article : Google Scholar : PubMed/NCBI